Rani Therapeutics says that it is “one step closer to our goal of making oral biologics a reality for patients with autoimmune diseases,” after initiating a Phase I clinical trial to evaluate the safety and tolerability of its proposed RT-111 orally administered ustekinumab biosimilar.
Rani Takes Next Step As Oral Ustekinumab Biosimilar Enters The Clinic
Oral Biologics Specialist Using Celltrion’s CT-P43 Candidate Under License
As biosimilars to Stelara (ustekinumab) continue to advance in global markets, Rani Therapeutics has made progress for its proposed RT-111 orally administered ustekinumab biosimilar.
